Matinas Biopharma (NYSEAMERICAN:MTNB) Stock Price Up 22% – Here’s What Happened

Shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) rose 22% on Friday . The company traded as high as $0.74 and last traded at $0.72. Approximately 125,477 shares traded hands during trading, an increase of 309% from the average daily volume of 30,690 shares. The stock had previously closed at $0.59.

Matinas Biopharma Stock Up 22.0%

The business has a fifty day simple moving average of $0.73 and a 200 day simple moving average of $1.24. The company has a market cap of $4.62 million, a price-to-earnings ratio of -0.21 and a beta of 1.28.

Matinas Biopharma (NYSEAMERICAN:MTNB) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.40) earnings per share for the quarter.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.